


Amendments to the Claims:

1. (Currently Amended) A compound of formula (I)



or a salt, or solvate thereof, ~~or physiologically functional derivative thereof~~,  
wherein:

n is an integer of from 2 to 8;

m is an integer of from 3 to 11, with the proviso that the sum of n + m is from 5 to 19;

R<sup>1</sup> is hydrogen or -XSO<sub>2</sub>NR<sup>6</sup>R<sup>7</sup>;

wherein X is -(CH<sub>2</sub>)<sub>p</sub> - or C<sub>2-6</sub> alkenylene;

p is an integer from 0 to 6;

R<sup>6</sup> and R<sup>7</sup> are independently selected from hydrogen, C<sub>1-6</sub>alkyl, C<sub>3-7</sub>cycloalkyl, CONR<sup>8</sup>R<sup>9</sup>, phenyl and phenyl(C<sub>1-4</sub>alkyl)-,

or R<sup>6</sup> and R<sup>7</sup>, together with the nitrogen atom to which they are bonded, form a 5-, 6- or 7- membered nitrogen – containing ring;

and  $R^6$  and  $R^7$  are each independently optionally substituted by 1 or 2 groups independently selected from halo,  $C_{1-6}$ alkyl,  $C_{1-6}$ alkoxy, hydroxy-substituted  $C_{1-6}$ alkoxy,  $C_{1-6}$ haloalkyl,  $CO_2R^8$ ,  $SO_2R^8R^9$ ,  $-CONR^8R^9$ ,  $-NR^8C(O)R^9$  or a 5-, 6- or 7-membered heterocyclic ring;


$R^8$  and  $R^9$  are independently selected from hydrogen,  $C_{1-6}$ alkyl,  $C_{3-7}$ cycloalkyl, phenyl and phenyl( $C_{1-6}$ alkyl)-;

$R^2$  and  $R^3$  are independently selected from hydrogen,  $C_{1-6}$ alkyl,  $C_{1-6}$ alkoxy, halo, phenyl and  $C_{1-6}$ haloalkyl;


$R^4$  and  $R^5$  are independently selected from hydrogen and  $C_{1-4}$  alkyl with the proviso that the total number of carbon atoms in  $R^4$  and  $R^5$  is not more than 4,

and


Ar is a group selected from the group consisting of:



(a)




(b)



(c)

and



(d)

wherein  $R^{11}$  represents hydrogen, halogen,  $-(CH_2)_qOR^{14}$ ,  $-NR^{14}C(O)R^{15}$ ,  $-NR^{14}SO_2R^{15}$ ,  $-SO_2NR^{14}R^{15}$ ,  $-NR^{14}R^{15}$ ,  $-OC(O)R^{16}$  or  $OC(O)NR^{14}R^{15}$ , and  $R^{10}$  represents hydrogen, halogen or  $C_{1-4}$  alkyl;

or  $R^{11}$  represents  $-NHR^{17}$  and  $R^{10}$  and  $-NHR^{17}$  together form a 5- or 6-membered heterocyclic ring;

$R^{12}$  represents hydrogen, halogen,  $-OR^{14}$  or  $-NR^{14}R^{15}$ ,  $-OC(O)R^{16}$  or  $OC(O)NR^{14}R^{15}$ ;

$R^{13}$  represents hydrogen, halogen, halo $C_{1-4}$  alkyl,  $-OR^{14}$  or  $-NR^{14}R^{15}$ ;

$R^{14}$  and  $R^{15}$  each independently represents hydrogen or  $C_{1-4}$  alkyl, or in the groups

$-NR^{14}R^{15}$ ,  $-SO_2NR^{14}R^{15}$  and  $-OC(O)NR^{14}R^{15}$ ,  $R^{14}$  and  $R^{15}$  independently represent hydrogen or  $C_{1-4}$  alkyl or together with the nitrogen atom to which they are attached form a 5-, 6- or 7- membered nitrogen-containing ring,

$R^{16}$  represents an aryl (eg phenyl or naphthyl) group which may be unsubstituted or substituted by one or more substituents selected from halogen,  $C_{1-4}$  alkyl, hydroxy,  $C_{1-4}$  alkoxy or halo  $C_{1-4}$  alkyl; and

q is zero or an integer from 1 to 4;

provided that when  $R^1$  is hydrogen

Ar is not a group (a) wherein;

$R^{11}$  is  $-(CH_2)_qOR^{14}$ , q is zero or 1 and  $R^{12}$  is  $OR^{14}$ ,

or  $R^{11}$  is  $-(CH_2)_qOR^{14}$ , q is zero and  $R^{13}$  is  $OR^{14}$ ,

or  $R^{11}$  is  $-NR^{14}SO_2R^{15}$  or  $NR^{14}COR^{15}$  and  $R^{12}$  is  $OR^{14}$ ,

or  $R^{11}$  and  $R^{13}$  both represent halogen and  $R^{12}$  is  $NR^{14}R^{15}$ ;

Ar is not a group (b) wherein  $R^{11}$  is  $-(CH_2)_qOR^{14}$  and  $R^{12}$  is  $OR^{14}$ ;

Ar is not a group (c),

and when  $R^1$  is  $XSO_2NR^6R^7$ , Ar is not a group (a) wherein

$R^{11}$  is  $(CH_2)_qOR^{14}$  or  $NR^{14}COR^{15}$ , and  $R^{12}$  is  $OR^{14}$ .

2. (Currently Amended) A compound of formula (I) according to claim 1 wherein, in the group Ar,  $R^{11}$  represents halogen,  $-(CH_2)_qOR^{14}$ ,  $-NR^{14}C(O)R^{15}$ ,  $-NR^{14}SO_2R^{15}$ ,  $-SO_2NR^{14}R^{15}$ ,  $-NR^{14}R^{15}$ ,  $-OC(O)R^{16}$  or  $OC(O)NR^{14}R^{15}$ ,

and  $R^{10}$  represents hydrogen,

or R<sup>11</sup> represents –NHR<sup>17</sup> and R<sup>10</sup> and –NHR<sup>17</sup> together form a 5- or 6-membered heterocyclic ring;

and

R<sup>13</sup> represents hydrogen, halogen, halo, C<sub>1-4</sub> alkyl, –OR<sup>14</sup>, or –NR<sup>14</sup>R<sup>15</sup>;

~~and all other substituents are as defined in claim 1.~~

3. (Currently Amended) A compound of formula (I) according to claim 1 ~~or claim 2~~ wherein the group R<sup>1</sup> is attached to the meta-position relative to the –O-(CH<sub>2</sub>)<sub>m</sub> link.


4. (Currently Amended) A compound of formula (I) according to claim 1 ~~any of claims 1 to 3~~ wherein R<sup>1</sup> represents SO<sub>2</sub>NR<sup>6</sup>R<sup>7</sup> wherein R<sup>6</sup> and R<sup>7</sup> are independently selected from hydrogen and C<sub>1-6</sub>alkyl.

5. (Currently Amended) A compound of formula (I) according to claim 1 ~~any of claims 1 to 4~~ wherein R<sup>4</sup> and R<sup>5</sup> are independently selected from hydrogen and methyl.


6. (Currently Amended) A compound of formula (I) according to claim 1 ~~any of claims 1 to 5~~ wherein R<sup>2</sup> and R<sup>3</sup> each represent hydrogen.

7. (Currently Amended) A compound of formula (I) according to claim 1 ~~any of claims 1 to 6~~ wherein n is 5 or 6 and m is 3 or 4 such that m + n is 8, 9 or 10.


8. (Currently Amended) A compound of formula (I) according to claim 1 ~~any of claims 1 to 7~~ wherein Ar represents a group selected from the group consisting of:




(i)




(ii)




(iii)




(iv)




(v)




(vi)




(vii)




(viii)




(ix)




(x)




(xi)




(xii)




(xiii)




(xiv)




(xv)




(xvi)




(xvii)



(xviii)



(xix)



(xx)

9. (Currently Amended) A compound of formula (I) according to claim 8 ~~any of claims 1 to 8~~ wherein  $R^1$  is hydrogen and Ar is selected from a the group consisting of structure (ii), (v), (vi), (viii), (ix), (xi), (xii), (xiii), (xiv), (xv), (xvi), (xvii) and (xviii).

10. (Currently Amended) A compound of formula (I) according to claim 8 ~~any of claims 1 to 8~~ wherein  $R^1$  is  $XSO_2NR^6R^7$  and Ar is selected from a the group consisting of structure (iii), (iv), (xiv), (xv), (xvi) and (xix).

11. (Currently Amended) A compound ~~of formula (I)~~ selected from the group consisting of:

8-Hydroxy-5-((1*R*)-1-hydroxy-2-[[6-(4-phenylbutoxy)hexyl]amino]ethyl)quinolin-2(1*H*)-one;

3-{4-[(6-[(2*R*)-2-Hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl]amino)hexyl]oxy}butyl}benzenesulfonamide;  
5-Hydroxy-8-(1-hydroxy-2-[(6-(4-phenylbutoxy)hexyl)amino]ethyl)-2*H*-1,4-benzoxazin-3(4*H*)-one;  
3-{4-[(6-[(2-hydroxy-2-(5-hydroxy-3-oxo-3,4-dihydro-2*H*-1,4-benzoxazin-8-yl)ethyl]amino)hexyl]oxy}butyl}benzenesulfonamide;  
4-Hydroxy-7-((1*R*)-1-hydroxy-2-[(6-(4-phenylbutoxy)hexyl)amino]ethyl)-1,3-benzothiazol-2(3*H*)-one;  
4-Hydroxy-7-(1-hydroxy-2-[(6-(4-phenylbutoxy)hexyl)amino]ethyl)-1,3-benzothiazol-2(3*H*)-one;  
3-{4-[(6-[(2*R*)-2-(3-Fluoro-4-hydroxyphenyl)-2-hydroxyethyl]amino)hexyl]oxy}butyl}benzenesulfonamide;  
3-(4-[(6-[(2-Hydroxy-2-[5-hydroxy-6-(hydroxymethyl)pyridin-2-yl]ethyl)amino)hexyl]oxy}butyl)benzenesulfonamide;  
3-[4-[(6-[(2*R*)-2-Hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)amino]phenyl}ethyl)amino]hexyl]oxy}butyl]benzenesulfonamide;  
3-{3-[(7-[(2*R*)-2-(3-Fluoro-4-hydroxyphenyl)-2-hydroxyethyl]amino)heptyl]oxy}propyl}benzenesulfonamide;  
3-(3-[(7-[(2-Hydroxy-2-[5-hydroxy-6-(hydroxymethyl)pyridin-2-yl]ethyl)amino]heptyl]oxy}propyl)benzenesulfonamide;  
3-[3-[(7-[(2*R*)-2-Hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)amino]phenyl}ethyl)amino]heptyl]oxy}propyl]benzenesulfonamide;  
3-{3-[(7-[(2*R*)-2-Hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl]amino)heptyl]oxy}propyl}benzenesulfonamide;  
3-(3-[(7-[(2*R*)-2-[3-(Formylamino)-4-hydroxyphenyl]-2-hydroxyethyl]amino)heptyl]oxy}propyl)benzenesulfonamide;

a salt thereof , and a solvate thereof, or physiologically functional derivative thereof.

12. (Currently Amended) A method for the prophylaxis or treatment of a clinical condition in a mammal, ~~such as a human~~, for which a selective  $\beta_2$ -adrenoreceptor agonist is indicated, which comprises administering ~~administration of~~ a therapeutically effective amount of a compound of formula (I) according to claim 1 ~~any of claims 1 to 11~~, or a pharmaceutically acceptable salt, or solvate thereof, ~~or physiologically functional derivative thereof~~.


13. (Canceled)

14. (Currently Amended) A pharmaceutical formulation comprising a compound of formula (I), according to claim 1 ~~any of claims 1 to 11~~, or a pharmaceutically acceptable salt, or solvate thereof, ~~or physiologically functional derivative thereof~~, and a pharmaceutically acceptable carrier or excipient, and optionally one or more other therapeutic ingredients.

15. (Canceled)


16. (Currently Amended) A process for the preparation of a compound of formula (I), according to claim 1 ~~any of claims 1 to 11~~, or a salt, or solvate thereof, ~~or physiologically functional derivative thereof~~, which comprises:

(a) deprotecting ~~deprotection of~~ a protected intermediate of formula (II):




or a salt or solvate thereof, wherein  $\text{R}^1$ ,  $\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $m$  and  $n$  are as defined for the compounds of formula (I)  $\text{R}^{25}$  represents an optionally protected form of Ar, and  $\text{R}^{26}$  and  $\text{R}^{27}$  each independently represent either hydrogen or a protecting group, provided that the compound of formula (II) contains at least one protecting group;

~~(b) — reacting a compound of formula (XIII):~~




~~Wherein Ar is as defined above with a compound of formula (VI):~~




(VI)

Wherein L is a leaving group such as halo (typically chloro, bromo or iodo) or a sulphonate (typically methanesulphonate) and  $\text{R}^1, \text{R}^2, \text{R}^3, \text{R}^4, \text{R}^5, n$  and  $m$  are as defined for compounds of formula (I).

(c) reacting a compound of formula (XV):




wherein L is a leaving group as hereinbefore defined, with an amine of formula (XVI):




(XVI)

wherein  $\text{R}^1, \text{R}^2, \text{R}^3, \text{R}^4, \text{R}^5, n$  and  $m$  are as defined for formula (I); and


(d) (i) reacting a compound of formula (XIII):




~~Wherein Ar is as hereinbefore defined and R<sup>34</sup> is a chiral auxiliary group,  
 with a compound of formula (XVII):~~



~~wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, n and m are as hereinbefore defined;  
 followed where necessary by removal of said chiral auxiliary group R<sup>34</sup>;  
 or (ii) reacting a compound of formula (XVIII):~~



~~wherein Ar is as hereinbefore defined; with an amine of formula (XVI):~~



~~as hereinbefore defined,~~

~~under conditions suitable to effect reductive amination,~~

wherein said process may further optionally comprise one or more of ~~followed~~  
~~by~~ the following steps in any order:

- (i) ~~optional removal of~~ removing any protecting groups;
- (ii) ~~optional separation of~~ separating an enantiomer from a mixture of enantiomers;
- (iii) ~~optional conversion of~~ converting the product to a corresponding salt, solvate, or
- (iv) ~~optional conversion of~~ converting a group  $R^1$ ,  $R^2$  and/or  $R^3$  to another group  $R^1$ ,  $R^2$  and/or  $R^3$ , ~~or physiologically functional derivative thereof.~~

17. (New) A compound of the formula (I) according to claim 1, wherein m is an integer ranging from 3 to 7.

18. (New) A compound of the formula (I) according to claim 1, wherein the sum of  $n + m$  ranges from 5 to 12.

19. (New) A compound of the formula (I) according to claim 1, wherein p is an integer ranging from 0 to 4.


20. (New) A method according to claim 12, wherein the mammal is a human.

21. (New) A method according to claim 12, wherein the clinical condition is asthma.


22. (New) A method according to claim 12, wherein the clinical condition is COPD.

23. (New) A process for the preparation of a compound of formula (I), according to claim 1 or a salt, or solvate thereof, which comprises:

reacting a compound of formula (XIII):



Wherein Ar is as defined above with a compound of formula (VI):



(VI)

wherein L is a leaving group and R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, n and m are as defined for compounds of formula (I);

wherein said process may further optionally comprise one or more of following steps in any order:

- (i) removing any protecting groups;
- (ii) separating an enantiomer from a mixture of enantiomers;
- (iii) converting the product to a corresponding salt, solvate, or
- (iv) converting a group R<sup>1</sup>, R<sup>2</sup> and/or R<sup>3</sup> to another group R<sup>1</sup>, R<sup>2</sup> and/or R<sup>3</sup>.

24. (New) A process according to claim 23, wherein the leaving group comprises a halo group.

25. (New) A process according to claim 24, wherein the halo group is selected from the group consisting of chloro, bromo, and iodo.

26. (New) A process according to claim 23, wherein the leaving group comprises a sulphonate group.


27. (New) A process according to claim 26, wherein the sulphonate group is a methanesulphonate group.

28. (New) A process for the preparation of a compound of formula (I), according to claim 1, or a salt or solvate thereof, which comprises:

reacting a compound of formula (XV):



wherein L is a leaving group, with an amine of formula (XVI):



wherein  $\text{R}^1$ ,  $\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $n$  and  $m$  are as defined for formula (I); and wherein said process may further optionally comprise one or more of the following steps in any order:

- (i) removing any protecting groups;
- (ii) separating an enantiomer from a mixture of enantiomers;
- (iii) converting the product to a corresponding salt, solvate, or
- (iv) converting a group  $\text{R}^1$ ,  $\text{R}^2$  and/or  $\text{R}^3$  to another group  $\text{R}^1$ ,  $\text{R}^2$  and/or  $\text{R}^3$ .

29. (New) A process according to claim 28, wherein the leaving group comprises a halo group.


30. (New) A process according to claim 28, wherein the halo group is selected from the group consisting of chloro, bromo, and iodo.

31. (New) A process according to claim 28, wherein the leaving group comprises a sulphonate group.

32. (New) A process according to claim 28, wherein the sulphonate group is a methanesulphonate group.


33. (New) A process for the preparation of a compound of formula (I), according to claim 1 or a salt or solvate thereof, wherein said process is selected from the group consisting of (i) and (ii):

(i) reacting a compound of formula (XIII):




Wherein Ar is as hereinbefore defined and R<sup>34</sup> is a chiral auxiliary group,

with a compound of formula (XVII):




wherein  $\text{R}^1$ ,  $\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $n$  and  $m$  are as hereinbefore defined;  
 optionally followed by removing said chiral auxiliary group  $\text{R}^{34}$ ;

and (ii) reacting a compound of formula (XVIII):



wherein Ar is as hereinbefore defined; with an amine of formula (XVI):



as hereinbefore defined,

under conditions suitable to effect reductive amination,

wherein said process may further optionally comprise one or more of the following steps in any order:

- (i) removing any protecting groups;
- (ii) separating an enantiomer from a mixture of enantiomers;
- (iii) converting the product to a corresponding salt, solvate,
- (iv) converting a group  $R^1$ ,  $R^2$  and/or  $R^3$  to another group  $R^1$ ,  $R^2$  and/or  $R^3$ .